N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
We spoke with Nigel today and asked about the progress the company is making and shareholders question.
N4 Pharma’s business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
The company was established in 2014 by Nigel Theobald, previously head of healthcare brands at Boots Group plc and founder of a series of successful businesses, including Oxford Pharmascience Group plc. Joining Nigel on N4 Pharma’s Board are Dr John Chiplin, who has significant operational, investment and transaction experience in the life science and technology industries, Dr David Templeton, pharmacology and pre-clinical drug discovery expert, Dr Chris Britten, an experienced pharmaceutical executive and Luke Cairns, Corporate Financier. You can read more about the board here.
